Back to results

A Study for the Transdermal Application of Teriparatide

Primary Purpose

Osteoporosis

Status

Completed

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

Subcutaneous Teriparatide

Transdermal Teriparatide

About this trial

This is an interventional treatment trial for Osteoporosis focused on measuring Age Related Osteoporosis, Senile Osteoporosis

Eligibility Criteria

55 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

Ambulatory, postmenopausal women.
Centrally confirmed lumbar spine or femoral neck bone mineral density (BMD) T-score of less than or equal to -2.5.
Without language barrier, cooperative, expected to return for all follow-up procedures, and have given informed consent after being informed of the risks, medications, and procedures to be used in the study.
Able to use the pen-type injection delivery system and the ViaDerm Teriparatide System satisfactorily in the opinion of the investigator, or with the help of a family member or caregiver.
Able to be reached by telephone for follow-up contact between visits

Exclusion Criteria:

Abnormal laboratory values for albumin and alkaline phosphatase.
Laboratory values outside the ranges defined in the protocol for the following: Serum calcium, intact parathyroid hormone (iPTH), 25 hydroxyvitamin D, and 24-hour urine calcium
History of diseases other than postmenopausal osteoporosis that affect bone metabolism, such as Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hypoparathyroidism, hyperparathyroidism, and intestinal malabsorption.
History of malignant neoplasms in the 5 years prior to randomization, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may be randomized.
Use of a pacemaker.
Known chronic dermatological disorder, such as contact dermatitis
History of allergy or sensitivity to tapes or adhesives
Patients prone to bleeding with coagulopathies, such as hemophilia or thrombocytopenia.
Patients who have an increased baseline risk of osteosarcoma, Paget's disease of the bone, or unexplained elevations of alkaline phosphatase; or prior external beam, implant radiation therapy involving the skeleton, or previous primary skeletal malignancy.
Major fracture within the past year in the femur, tibia, humerus, or radius (with or without ulna).

Treatment with:

calcitonins in the 2 months prior to randomization.
oral, transdermal/patch, or injectable estrogens, progestins, estrogen analogs, estrogen agonists, estrogen antagonists, selective estrogen receptor modulators, or tibolone in the 3 months prior to randomization; treatment with intravaginal estrogens in doses higher than 0.3 mg of conjugated equine estrogen, or the equivalent, for more than 3 doses per week in the 3 months prior to randomization.
androgens or other anabolic steroids in the 6 months prior to randomization.
fluorides in the 2 years prior to randomization. (Previous or current use of fluoridated water or topical dental fluoride treatments are permitted.)
oral bisphosphonates for more than 2 consecutive months in the 6 months prior to randomization; treatment with intravenous bisphosphonates in the 6 months prior to randomization; treatment with more than 1 cycle of intermittent oral bisphosphonates in the 6 months prior to randomization; or having received the last cycle of this intermittent oral regimen less than 4 weeks prior to screening.
patients receiving intravenous zoledronic acid during the 12 months prior to randomization.
vitamin D greater than 50,000 International Units (IU) per week or with any dose of calcitriol or vitamin D analogs or agonists in the 6 months prior to randomization.
systemic corticosteroids in the 1 month prior to randomization or for more than 30 days in the 1 year prior to randomization. (Ophthalmic, otic, topical, orally inhaled, nasally inhaled, or intra-articular corticosteroid therapy may be used without these restrictions.)
any other drug known to significantly affect bone metabolism in the 6 months prior to randomization.
warfarin or other coumadin anticoagulants in the 1 month prior to randomization.
any investigational drug in the 1 month prior to entry into the study.

Sites / Locations

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Experimental

Arm Label

20 mcg Subcutaneous Teriparatide

30 mcg Transdermal Teriparatide

50 mcg Transdermal Teriparatide

80 mcg Transdermal Teriparatide

Arm Description

Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.

Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.

Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.

Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.

Outcomes

Primary Outcome Measures

Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months

Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model and least square (LS) means were adjusted for baseline BMD values as a covariate and pooled site and treatment as fixed effects.

Secondary Outcome Measures

Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 6 Months

Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.

Time Course Change of BMD Response at the Lumbar Spine

To assess the time course of the treatment, the BMD data of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) and analyzed using a mixed model repeated measures (MMRM) method, with the repeated measure occurring at each visit (for example, 6 and 12 month). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).

Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)

Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.

Percent Change From Baseline of C-Terminal Telopeptide (CTX)

C-terminal telopeptide is a marker of bone resorption.

Percent Change From Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 Month

Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.

Convenience/Ease of Use Questionnaire (CEUQ)

CEUQ consists of 5 sections and 16 questions using a 5-point Likert scale designed to collect measures for ease of use (S1), convenience of use (S2), confidence of use (S3), fear of use (S4), and overall satisfaction with therapy (S5). CEUQ is not a validated instrument.

Change in Serum Calcium With and Without Adjustments for Serum Albumin From Predose to After 4 and 6 Hours

Serum calcium adjusted for serum albumin levels is calculated using the following formula: Total Calcium + [(40 - albumin) x 0.02]. Analysis for serum calcium and albumin adjusted serum calcium were collected at predose, 4 hours (h) post-dose (PD) and 6 h PD at baseline and 12 months (mon).

Change From Baseline in Urine Calcium Excretion at 6 and 12 Months

Change From Pre-dose and Postdose Supine and Standing SBP and DBP at Baseline (BL) and 12 Months (Mon)

Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) measured at pre-dose and 30 minutes (min) and 2 hours (hr) post-dose in both the supine and standing position.

Change From Pre-dose to Postdose in Supine and Standing Heart Rate at Baseline (BL) and 12 Months (Mon).

Number of Participants With Parathyroid Hormone (PTH) Specific Antibody Levels

Participants were tested for anti-recombinant teriparatide and anti-synthetic teriparatide titers. Either none were detected (ND) or antibodies were determined to be present if the teriparatide specific antibody titers were at least 1:8 (titer 1:8).

Pharmacokinetics Parameters: Area Under the Curve (AUC)

Due to high intra-subject variability, data was not analyzed for this outcome measure.

Pharmacokinetics Parameters: Maximal Concentration (Cmax)

Due to high intra-subject variability, data was not analyzed for this outcome measure.

DRAIZE Edema Assessment at Baseline Through 13 Month Follow-up

Severity of edema was categorized based on a 5 point scale: 0=no edema, 4=severe edema (defined as an area raised more than 1 millimeter and extending beyond area of exposure)

DRAIZE Erythema Assessment at Baseline Through 13 Month Follow-up

Severity of erythema was categorized based on a 5 point scale: 0=no erythema, 4=severe erythema (defined as beet red to eschar)

Full Information

NCT ID

NCT01011556

First Posted

November 9, 2009

Last Updated

September 21, 2012

Sponsor

Eli Lilly and Company

Collaborators

TransPharma Medical

1. Study Identification

Unique Protocol Identification Number

NCT01011556

Brief Title

A Study for the Transdermal Application of Teriparatide

Official Title

A Phase 2 Study for Transdermal Application of Teriparatide

Study Type

Interventional

2. Study Status

Record Verification Date

September 2012

Overall Recruitment Status

Completed

Study Start Date

November 2009 (undefined)

Primary Completion Date

September 2011 (Actual)

Study Completion Date

September 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Eli Lilly and Company

Collaborators

TransPharma Medical

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The primary purpose of this study is to help answer the following research questions: How teriparatide given using a skin patch (transferred through the skin using the ViaDerm Teriparatide System) compares to teriparatide injected under the skin with a needle (pen injector) affects your bone density (how solid or porous your bones are). The safety of the teriparatide skin patch and any side effects that might be associated with it.

Detailed Description

Teriparatide 20 micrograms (mcg) per day is currently only available as a subcutaneous (SQ) injection and many patients with severe osteoporosis for whom anabolic therapy with teriparatide is appropriate are either unwilling or physically unable to self-inject. The purpose of this Phase 2 study is to identify a transdermal dose or doses that will be comparable to the teriparatide 20 mcg SQ dose from a pharmacodynamic (PD) and safety standpoint for use in future Phase 3 studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Osteoporosis

Keywords

Age Related Osteoporosis, Senile Osteoporosis

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigator

Allocation

Randomized

Enrollment

233 (Actual)

8. Arms, Groups, and Interventions

Arm Title

20 mcg Subcutaneous Teriparatide

Arm Type

Active Comparator

Arm Description

Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.

Arm Title

30 mcg Transdermal Teriparatide

Arm Type

Experimental

Arm Description

Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.

Arm Title

50 mcg Transdermal Teriparatide

Arm Type

Experimental

Arm Description

Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.

Arm Title

80 mcg Transdermal Teriparatide

Arm Type

Experimental

Arm Description

Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.

Intervention Type

Drug

Intervention Name(s)

Subcutaneous Teriparatide

Other Intervention Name(s)

recombinant human parathyroid hormone (rhPTH) (1-34), recombinant human teriparatide, Forteo, Forsteo, LY333334

Intervention Description

Administered subcutaneously once daily for 12 months

Intervention Type

Drug

Intervention Name(s)

Transdermal Teriparatide

Other Intervention Name(s)

synthetic human parathyroid hormone (shPTH) (1-34), synthetic human teriparatide

Intervention Description

Administered transdermally, applied once daily for 6 hours over 12 months

Primary Outcome Measure Information:

Title

Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months

Description

Time Frame

Baseline, 12 Months

Secondary Outcome Measure Information:

Title

Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 6 Months

Description

Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.

Time Frame

Baseline, 6 Months

Title

Time Course Change of BMD Response at the Lumbar Spine

Description

Time Frame

Baseline to 6 Months and 12 Months

Title

Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)

Description

Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.

Time Frame

Baseline, 1 Month, 3 Months, 6 Months, 12 Months

Title

Percent Change From Baseline of C-Terminal Telopeptide (CTX)

Description

C-terminal telopeptide is a marker of bone resorption.

Time Frame

Baseline, 1 Month, 3 Months, 6 Months, 12 Months

Title

Percent Change From Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 Month

Description

Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.

Time Frame

Baseline, 1 Month

Title

Convenience/Ease of Use Questionnaire (CEUQ)

Description

Time Frame

baseline up to 12 months

Title

Change in Serum Calcium With and Without Adjustments for Serum Albumin From Predose to After 4 and 6 Hours

Description

Time Frame

Baseline, 12 Months

Title

Change From Baseline in Urine Calcium Excretion at 6 and 12 Months

Time Frame

Baseline, 6 Months, 12 Months

Title

Change From Pre-dose and Postdose Supine and Standing SBP and DBP at Baseline (BL) and 12 Months (Mon)

Description

Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) measured at pre-dose and 30 minutes (min) and 2 hours (hr) post-dose in both the supine and standing position.

Time Frame

Pre-Dose, 30 minutes, 2 hours Post-Dose at Baseline and 12 Months

Title

Change From Pre-dose to Postdose in Supine and Standing Heart Rate at Baseline (BL) and 12 Months (Mon).

Time Frame

Pre-dose, 30 minutes, 2 hours at Baseline and 12 Months

Title

Number of Participants With Parathyroid Hormone (PTH) Specific Antibody Levels

Description

Time Frame

Baseline and 1, 3, 12, and 13 Months (mon)

Title

Pharmacokinetics Parameters: Area Under the Curve (AUC)

Description

Due to high intra-subject variability, data was not analyzed for this outcome measure.

Time Frame

Baseline, 1 Month, 3 Months, and 12 Months

Title

Pharmacokinetics Parameters: Maximal Concentration (Cmax)

Description

Due to high intra-subject variability, data was not analyzed for this outcome measure.

Time Frame

Baseline, 1 Month, 3 Months, 12 Months

Title

DRAIZE Edema Assessment at Baseline Through 13 Month Follow-up

Description

Severity of edema was categorized based on a 5 point scale: 0=no edema, 4=severe edema (defined as an area raised more than 1 millimeter and extending beyond area of exposure)

Time Frame

13 Month follow-up

Title

DRAIZE Erythema Assessment at Baseline Through 13 Month Follow-up

Description

Severity of erythema was categorized based on a 5 point scale: 0=no erythema, 4=severe erythema (defined as beet red to eschar)

Time Frame

13 Month follow-up

10. Eligibility

Sex

Female

Minimum Age & Unit of Time

55 Years

Maximum Age & Unit of Time

80 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Ambulatory, postmenopausal women. Centrally confirmed lumbar spine or femoral neck bone mineral density (BMD) T-score of less than or equal to -2.5. Without language barrier, cooperative, expected to return for all follow-up procedures, and have given informed consent after being informed of the risks, medications, and procedures to be used in the study. Able to use the pen-type injection delivery system and the ViaDerm Teriparatide System satisfactorily in the opinion of the investigator, or with the help of a family member or caregiver. Able to be reached by telephone for follow-up contact between visits Exclusion Criteria: Abnormal laboratory values for albumin and alkaline phosphatase. Laboratory values outside the ranges defined in the protocol for the following: Serum calcium, intact parathyroid hormone (iPTH), 25 hydroxyvitamin D, and 24-hour urine calcium History of diseases other than postmenopausal osteoporosis that affect bone metabolism, such as Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hypoparathyroidism, hyperparathyroidism, and intestinal malabsorption. History of malignant neoplasms in the 5 years prior to randomization, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may be randomized. Use of a pacemaker. Known chronic dermatological disorder, such as contact dermatitis History of allergy or sensitivity to tapes or adhesives Patients prone to bleeding with coagulopathies, such as hemophilia or thrombocytopenia. Patients who have an increased baseline risk of osteosarcoma, Paget's disease of the bone, or unexplained elevations of alkaline phosphatase; or prior external beam, implant radiation therapy involving the skeleton, or previous primary skeletal malignancy. Major fracture within the past year in the femur, tibia, humerus, or radius (with or without ulna). Treatment with: calcitonins in the 2 months prior to randomization. oral, transdermal/patch, or injectable estrogens, progestins, estrogen analogs, estrogen agonists, estrogen antagonists, selective estrogen receptor modulators, or tibolone in the 3 months prior to randomization; treatment with intravaginal estrogens in doses higher than 0.3 mg of conjugated equine estrogen, or the equivalent, for more than 3 doses per week in the 3 months prior to randomization. androgens or other anabolic steroids in the 6 months prior to randomization. fluorides in the 2 years prior to randomization. (Previous or current use of fluoridated water or topical dental fluoride treatments are permitted.) oral bisphosphonates for more than 2 consecutive months in the 6 months prior to randomization; treatment with intravenous bisphosphonates in the 6 months prior to randomization; treatment with more than 1 cycle of intermittent oral bisphosphonates in the 6 months prior to randomization; or having received the last cycle of this intermittent oral regimen less than 4 weeks prior to screening. patients receiving intravenous zoledronic acid during the 12 months prior to randomization. vitamin D greater than 50,000 International Units (IU) per week or with any dose of calcitriol or vitamin D analogs or agonists in the 6 months prior to randomization. systemic corticosteroids in the 1 month prior to randomization or for more than 30 days in the 1 year prior to randomization. (Ophthalmic, otic, topical, orally inhaled, nasally inhaled, or intra-articular corticosteroid therapy may be used without these restrictions.) any other drug known to significantly affect bone metabolism in the 6 months prior to randomization. warfarin or other coumadin anticoagulants in the 1 month prior to randomization. any investigational drug in the 1 month prior to entry into the study.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Organizational Affiliation

Eli Lilly and Company

Official's Role

Study Director

Facility Information:

Facility Name

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

City

Buenos Aires

ZIP/Postal Code

C1128AAF

Country

Argentina

Facility Name

City

Parnu

ZIP/Postal Code

80010

Country

Estonia

Facility Name

City

Tallin

ZIP/Postal Code

10138

Country

Estonia

Facility Name

City

Tartu

ZIP/Postal Code

50410

Country

Estonia

Facility Name

City

Balatonfured

ZIP/Postal Code

8230

Country

Hungary

Facility Name

City

Budapest

ZIP/Postal Code

1036

Country

Hungary

Facility Name

City

Debrecen

ZIP/Postal Code

4043

Country

Hungary

Facility Name

City

Esztergom

ZIP/Postal Code

2500

Country

Hungary

Facility Name

City

Gyor

ZIP/Postal Code

9023

Country

Hungary

Facility Name

City

Szombathely

ZIP/Postal Code

H-9700

Country

Hungary

Facility Name

City

Tatabanya

ZIP/Postal Code

2800

Country

Hungary

Facility Name

City

Guadalajara

ZIP/Postal Code

44158

Country

Mexico

Facility Name

City

Mexico City

ZIP/Postal Code

03300

Country

Mexico

Facility Name

City

Monterrey

ZIP/Postal Code

64460

Country

Mexico

Facility Name

City

Bucharest

ZIP/Postal Code

011025

Country

Romania

Facility Name

City

Cluj-Napoca

ZIP/Postal Code

400006

Country

Romania

Facility Name

City

Lasi

ZIP/Postal Code

700111

Country

Romania

Facility Name

City

Timisoara

ZIP/Postal Code

300736

Country

Romania

12. IPD Sharing Statement

Learn more about this trial

A Study for the Transdermal Application of Teriparatide

We'll reach out to this number within 24 hrs